What is Eucrisa?
Eucrisa is an ointment that is used to treat mild to moderate cases of eczema, a chronic and inflammatory skin condition. This prescription medication contains crisaborole, a compound that helps to reduce the inflammation and itching associated with eczema.
Eucrisa is approved by the US Food and Drug Administration (FDA) as a safe and effective option for the treatment of eczema in both children and adults. It is available in two formulations, a 2% ointment and a 0.03% topical solution, and is generally applied twice daily to the affected skin areas.
Patients with eczema who use Eucrisa usually see an improvement in their symptoms within about two weeks of starting the treatment. The medication has been shown to reduce itching, redness, and swelling, leading to overall improvement of the condition.
Eucrisa is typically well-tolerated, with minimal side effects. Some of the most common side effects include burning, stinging, or itching at the application site. In rare cases, more serious side effects such as allergic reactions, hives, or swelling may occur.
Overall, Eucrisa is an effective and safe option for the treatment of eczema, although it is important to consult with a healthcare professional to determine whether it is appropriate for a specific individual and to discuss potential side effects and interactions with other medications.
Frequently Asked Questions about eucrisa
EUCRISA is a prescription ointment used on the skin (topical) to treat mild-to-moderate eczema (atopic dermatitis) in adults and children 3 months of age and older. Patient Information .
EUCRISA is a topical ointment that works at and below the skin's surface. It's designed to block PDE4 enzymes within the skin. The specific way EUCRISA works is not well defined.
EUCRISA® (crisaborole) Safety Info. continue viewing this site. Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve.
Each gram of EUCRISA contains 20 mg of crisaborole in an ointment containing white petrolatum, propylene glycol, mono- and di-glycerides, paraffin, butylated hydroxytoluene, and edetate calcium disodium.
EUCRISA can be used on your skin wherever you have eczema, including on your face. EUCRISA is for topical use only. Do not use in eyes, mouth, or vagina. The most common side effect of EUCRISA is application site pain, such as burning or stinging.
In trials of people ages 2 and up, more people using EUCRISA twice daily (32%) achieved clear or almost clear skin vs. those using non-medicated ointment (22%) after 28 days. Some saw clear or almost clear skin in about a week (8 days).
EUCRISA can be used on your skin wherever you have eczema, including on your face. EUCRISA is for topical use only. Do not use in eyes, mouth, or vagina. The most common side effect of EUCRISA is application site pain, such as burning or stinging.
Eucrisa only comes as a brand-name drug. It's not currently available in a generic version. A generic drug contains an exact copy of the active drug in a brand-name medication but tends to cost less.
See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. * Sections or subsections omitted from the full prescribing information are not listed. EUCRISA is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.
Use EUCRISA exactly as your healthcare provider tells you to use it. Apply a thin layer of EUCRISA to the affected areas 2 times each day. If flares have improved, your doctor may suggest reducing your use of EUCRISA to once daily. Wash your hands after applying EUCRISA, unless hands are being treated.
How long can you use Eucrisa? You should use it for as long as your doctor has told you to use it. The clinical trial (AD-303) studied the safety of using Eucrisa for 48 weeks in patients over 2 years of age. The result was that it had a favorable safety profile.
How long can you use Eucrisa? You should use it for as long as your doctor has told you to use it. The clinical trial (AD-303) studied the safety of using Eucrisa for 48 weeks in patients over 2 years of age. The result was that it had a favorable safety profile.
In trials of people ages 2 and up, more people using EUCRISA twice daily (32%) achieved clear or almost clear skin vs. those using non-medicated ointment (22%) after 28 days. Some saw clear or almost clear skin in about a week (8 days).
